Dzherelo (Immunoxel) as Adjunctive Therapy to Standard Antituberculosis Treatment in Patients with Pulmonary Tuberculosis: A Systematic Review and Meta-analysis of Clinical Trials

Marcel Kitenge  
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Bessie Phiri  
Directorate of clinical Services, Ministry of Health, Clinical services, Lilongwe.

Sara M Pheeha  
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town.

Modupe Ogunrombi  
Department of Pharmacology, Sefako Makgatho Health Sciences University Faculty of Health Sciences, Pretoria.

Peter Nyasulu (pnyasulu@sun.ac.za)  
Stellenbosch University Faculty of Medicine and Health Sciences  https://orcid.org/0000-0003-2757-0663

Research

Keywords: Immunoxel, Dzherelo, Tuberculosis, Anti-tuberculosis treatment (ATT), adjunctive therapy, meta-analysis, clinical trials, immunotherapy

DOI: https://doi.org/10.21203/rs.3.rs-121904/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Dzherelo (Immunoxel) is one of the few approved immunomodulators that has been shown to produce positive treatment outcomes in patients with tuberculosis (TB). The aim of this review was to assess the effectiveness of Immunoxel used as adjunct therapy with conventional anti-TB therapy for the treatment of pulmonary TB.

Methods

Comprehensive search was conducted in different major databases: Pubmed (MEDLINE), EMBASE (OVID), Cochrane Central Register of Controlled Trials (CENTRAL), SCOPUS (Elsevier). We also searched Google Scholar along with trial registries and hand-searched the reference list of identified original research as well as review articles. Conference proceedings of relevant TB and lung diseases annual conferences were also screened. Two independent authors extracted outcomes data using a standardized extraction form. Relative risk (RR), mean difference (MD) and standardised mean difference (SMD) with a 95% confidence interval (CI) were used as measures of effect. We assessed certainty of evidence using GRADE.

Results

Six clinical trials, which met the criteria for the review were identified and these provided data for the review. Overall results from the six trials that compared anti-tuberculosis treatment (ATT) alone versus ATT and Immunoxel, ATT and Placebo versus ATT and Immunoxel, showed an increased number of patients becoming sputum-negative in the Immunoxel group (RR 3.19; 95% CI 2.44 to 4.17; 488 participants). There was also great reduction in body temperature among patients receiving Immunoxel compared to ATT alone (MD -0.20, 95% CI -0.22 to -0.18, 345 participants). However, there were no differences in body weight changes across all the studies (MD 5.65; 95% CI: -0.80 to 12.11; 382 participants).

Conclusion

Current evidence indicates that the use of Immunoxel as an adjunctive treatment in patients with pulmonary tuberculosis has the potential to enhance the efficacy of anti-tuberculosis treatment. However, well-designed, conducted and adequately powered clinical trials are needed to establish the effectiveness of this adjunctive treatment.

PROSPERO registration number: CRD42019127823

Background
Tuberculosis (TB) has existed for decades and remain one of the major public health concerns [1]. In 2019, 1.4 million deaths that are due to TB were recorded including an estimated 10 million new incident cases worldwide [1]. Drug resistant TB continues to be a threat to TB management despite the fact that, with a timely diagnosis and appropriate treatment, most of the people who contract TB could be cured [1]. The standard treatment regimens for latent TB infection take 3–9 months and new incident cases of TB require at least 6 months of treatment with multiple drugs [2]. A decline in the success rate of treatment and the increase in multidrug-resistant TB or rifampicin-resistant TB (MDR/RR-TB) indicate the urgent need for better treatment options [1, 2]. One of the interventions that could be employed in addressing these challenges is immunotherapy. This is believed to enhance the efficacy of TB chemotherapy and to potentially shorten the treatment duration [3].

Currently, it is becoming increasingly clear that an effective TB therapy, in addition to suppression of Mycobacterium tuberculosis replication must also enhance the host’s own immune response. However, candidate immunomodulators capable of inducing proper immune response are rare and not readily available. Dzherelo (Immunoxel) is one of the few approved immunomodulators that has shown to produce positive outcomes in patients with TB. Immunoxel, was formulated in 1980 by a Ukrainian scientist Volodymyr Pylypchuk (Ekomed company) and is currently widely available in Ukraine as an oral immunomodulating agent [4]. The Ministry of Health in Ukraine approved the formulation of Immunoxel in 1997 as a dietary herbal supplement following comprehensive laboratory and clinical testing [5]. In 2016, Immunoxel was officially approved as an oral immunomodulator by Ukrainian Ministry of Health.

Many clinical studies involving patients with or without HIV/TB co-infection were carried out in Ukraine to assess the effectiveness of Immunoxel [5–7]. Approximately 90% of patients included in these studies reported subjective improvement in their well-being, as demonstrated by an increase in body weight, improved liver function, and decrease in incidence of opportunistic infections [8]. Moreover, by the 6th month of follow-up, the proportion of cured TB patients by culture and radiology was about 2–4 folds higher than of those who received standard first-line anti-tuberculosis treatment (ATT) alone [5].

Immunoxel can also eliminate Mycobacterium tuberculosis and this is proved by accelerating sputum conversion, improving chest image, especially cavity closure, and improved overall respiratory function as well as clinical features such as reversal of weight loss, correction of the hepatotoxicity caused by TB drugs and increase in the absolute number of CD4 and CD8 T-lymphocytes [6]. In addition, the use of this immunomodulator alongside with ATT has been proven to shorten the duration of treatment as compared to using standard ATT alone [6]. Although several clinical trials have been conducted to date, this evidence has not yet been assessed in a systematic review. We therefore conducted a systematic review of the current existing evidence to assess effectiveness of adjunct Immunoxel with conventional anti-TB therapy for the treatment of pulmonary tuberculosis.

Materials And Methods
The methods of this systematic review and meta-analysis was reported as per the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) checklist. We registered the protocol for this systematic review on the International Prospective Register of Systematic Reviews (PROSPERO) with a registration number: CRD42019127823.

**Types of studies**

We included randomised and non-randomised controlled trials (RCT and non-RCT) that evaluated the adjunct effects of Immunoxel in TB patients allocated to adjunct Immunoxel with standard-of-care anti-TB treatment (standard TB treatment) and Standard TB treatment with placebo or standard TB treatment alone or standard TB treatment with other combination adjunctive therapies.

**Types of participants**

We included pulmonary TB patients older than 18 years, irrespective of resistance types.

**Types of interventions**

- Intervention group: adjunct Immunoxel with standard-of-care anti-TB treatment (standard TB treatment)
- Comparison group: Standard TB treatment with placebo or standard TB treatment alone.

We did not impose any restrictions on study interventions, such as dose, timing of outcomes measurement, duration of treatment etc.

**Types of outcomes measures**

**Primary outcome**

The primary outcome for this review was sputum smear conversion. This is defined as the proportion of patients with sputum that has been converted to negative at a certain point in time after initiation of anti-TB treatment and are therefore no longer infectious.

**Secondary outcome**

- **Safety**

We defined safety as the occurrence after initiation of the study drug treatment, of either:

- The change in body weight from baseline ($p < 0.05$) by the end of study.
- The change in liver function (levels of alanine transaminase and total bilirubin) from baseline ($p < 0.05$) by the end of the study.

**Electronic searches**
A comprehensive and exhaustive search was performed by MKK, one of the three review authors, with the help of an Information Specialist to identify relevant studies in the following electronic databases: Pubmed (MEDLINE), EMBASE (OVID), Cochrane Central register of controlled trials (CENTRAL), SCOPUS (Elsevier). We searched Google Scholar and also looked for ongoing RCTs of adjunctive therapies in TB in the following registries:

- US National Institute of Health Ongoing Trials Register (www.clinicaltrials.gov)
- World Health Organisation International Clinical Trials Register Platform (WHO ICTRP) (www.who.int/ictrp)
- Pan African Clinical Trials Registry (PACTR) (www.pactr.samrc.ac.za)

Searches were run on 21 May 2020 and were not restricted to date, language nor publication status. Detailed search strategies are presented in appendix A.

**Searching other resources**

We also hand-searched the reference list of identified research articles. Conference proceedings of the International Union against Tuberculosis and Lung Disease (IUATLD) World Congress, The European Respiratory Society World Congress Conferences and the American Thoracic Society International Congress were screened in order to retrieve information on any further trials that may not have been included in the electronic database.

**Study Selection**

Three review authors (MKK, BP and SM) independently screened the titles and abstracts obtained from the electronic searches, as well as full texts of all potentially eligible studies using a standardised eligibility form with predefined inclusion criteria. Disagreement between the authors who assessed study eligibility were resolved by discussion and consensus.

**Data extraction and management**

Two review authors (MKK and BP) independently extracted data from included studies using a standardised data extraction form and performed risk of bias assessment. Extracted information included details of the study, participants, interventions and outcomes. Moreover, we assessed the risk of bias for RCTs using the Cochrane risk of bias for randomized controlled trials as described in Cochrane Handbook for Systematic Reviews of Interventions [9]. Thus, the assessment of risk of bias took into account the variation in the study designs (RCTs and non-RCTs), as certain criteria were only applicable to RCTs and others were only applicable to non-randomised studies.

Disagreement between authors who extracted the data and assessed the risk of bias were resolved by discussion and consensus. We planned to assess for publication bias using funnel plot, but this was not done due the insufficient number of studies included in this review. Data were entered into the Review Manager 5.4 statistical Software [10].
Statistical analysis

Dichotomous data were presented and compared using risk ratio while continuous outcomes were presented and compared using mean difference (MD). Furthermore, as studies used different units to measure some of the biochemical parameters, standardised mean difference (SMD) was used to present and compared data, we assumed SMD of 0.2 to represent a small effect, 0.5 a medium effect and 0.8 a large effect accordingly [11]. All measures of effect were reported with their corresponding 95% confidence intervals (CI).

We assessed heterogeneity between trial results by visually inspecting the forest plots for overlapping confidence intervals, followed by the chi-squared test of homogeneity (with significance defined at an alpha of 10%). We then used the I² test to quantify the degree of heterogeneity. We conducted meta-analysis when included studies were similar in terms of interventions, participants, and outcomes. We pooled the results using Mantel-Haenszel method and fixed model effects. When there was substantial heterogeneity, we used random-effects model. When I² was greater than 50%, we considered it to be substantial heterogeneity and explored the cause of heterogeneity using subgroup analyses. All the analyses were performed using RevMan 5.4.

Finally, GRADE approach [12–14] was used to assess the quality of evidence for the adjunct effect of immunoxel. We recorded the quality of evidence as high, moderate, low or very low.

Results

Study flow chart and description of studies

Results of study selection processes are described in a flow diagram (Fig. 1). We identified 25 records through a comprehensive and exhaustive search. Twenty-five titles and abstracts were screened and 10 articles were deemed to be irrelevant. Following the full text assessment, independent review and discussion, of the remaining 15 full text articles, we included 6 studies [5, 6, 7, 8, 15, 16]. We have provided reasons for excluding irrelevant studies in Table 1.

Excluded studies

Zulkifi et al. [17] and Prihoda et al. [21] were excluded because they were not clinical trials. Butov and colleagues [18] were excluded because the intervention used is not under this review. Nikolaeva et al. [19–20] was excluded because their study did not report any of the study outcomes in this review. Studies [4, 8, 23] were excluded after finding out that they were duplicate studies and therefore were results of a publication bias (studies published in two different journals using different titles). Furthermore, Prihoda et al. [22] was excluded because the study used Immunoxel combined with other forms of immunotherapies. The details for exclusion of studies are provided in Table 1.
Table 1
Characteristics of excluded studies

| Study          | Reason for exclusion                                                                 |
|----------------|---------------------------------------------------------------------------------------|
| Amin 2020      | This was a review [4]                                                                  |
| Zulkifli 2017  | Study was a systematic review [17]                                                     |
| Butov 2012     | Study used V-5 Immunitor, an intervention not under this review [18]                   |
| Nikolaeva 2008 | The study did not report the outcomes of interest [19]                                  |
| Nikolaeva 2008 | This study [8] was duplicate of duplicate of study [19]                                |
| Nikolaeva 2009 | The study did not report any of the outcomes of interest, the study looked particularly at the effect of Dzherelo on immunological and virological responses (T-lymphocyte and viral load among TB/HIV patients) [20]. |
| Prihoda 2007   | Not a comparative study, in addition, all the participants received the intervention in combination with some other immunomodulators [21]. |
| Prihoda 2009   | The study compared Dzherelo (immunoxel) with other forms of immunotherapies (Svitanok, and Lizorm) [22]. |
| Prihoda 2008   | This study [23] was a duplicate of study [21].                                          |

Included studies

We provided detailed information of included studies and summarise key features below (Table 2). All studies were conducted in Ukraine, including one multicentre conducted in Ukraine and Mongolia [5]. Two studies were open-label RCT, one double blinding placebo RCT, one unblinding RCT and one clinical trial with unspecified methods. Batbold et al. [5] was the most powered of the studies included in this review (269 participants). Zaiteva et al. enrolled 75 newly diagnosed TB patients [8]. Efremenko et al. randomly allocated 69 participants to one of the four different types of Immunoxel formulations [7]. Furthermore, Zaiteva et al. colleagues matched 66 participants to receive either individualised ATT or ATT with liquid Immunoxel [16]; and Arjanova et al. matched 40 participants to receive either ATT or ATT with Immunoxel [15]. The study population for five trials were in-patients, however one trial did not clearly specify its study population as to whether they were in-patients or out-patients.

Four studies compared liquid-based formulation, 50 drops of Immunoxel twice daily, with placebo [6, 8, 15, 16]. One study compared four different formulations of Immunoxel given once per day [7], and one study compared unspecified Immunoxel to placebo [5].
Table 2
Characteristics of included studies

| Trials         | Country          | Study Design                      | Number of participants | Intervention                      | Comparator            | Ref  |
|----------------|------------------|-----------------------------------|------------------------|-----------------------------------|-----------------------|------|
| Arjanova 2009  | Ukraine          | Open-label trial                  | 40 TB/HIV coinfected patients | Immunoxel with ATT                | ATT alone             | [15] |
| Arjonova 2010  | Ukraine          | Open-label trial                  | 40 TB/HIV coinfected patients | Immunoxel with ATT                | ATT alone             | [6]  |
| Batbold 2017   | Ukraine and Mongolia | Double blinding place controlled RCT | 269 participants | Immunoxel with ATT                | ATT with placebo      | [5]  |
| Efremenko 2012 | Ukraine          | Unblinded RCT                     | 69 patients, 76.8% with TB and 23.2% with TB/HIV co-infection | Various immunoxel formulations: Sugar dragees, sugar-coated pills, Gelatin pastilles and dried-honey lozenges | Sugar-coated pills without immunoxel | [7]  |
| Zaiteva 2009   | Ukraine          | Non-Randomised controlled trial   | 75 newly PTB patients with to assess the adjunct effect of Dzherelo on clinical outcomes and biochemical and blood parameters in patients with cavitary and infiltrating PTB | Immunoxel with ATT    | ATT only              | [8]  |
| Zaiteva 2009a  | Ukraine          | Non-Randomised controlled trial   | 66 patients of which 48 had MDR-TB | Immunoxel with ATT    | ATT alone              | [16] |

ATT: Anti-tuberculosis therapy, RCT: randomised controlled trial

Risk of bias

A graphical representation of the overall risk of bias in the included studies is presented in Fig. 2 and Fig. 3. All trials had a higher risk of bias due to unreported, inadequate or unclear methods of random sequence generation and lack of allocation concealment. Three studies [6, 7, 15, 16] did not report how the allocation was generated. Balbold et al. [5] used a computer to generate the allocation while Zaiteva...
et al. [8] did not allocate groups randomly. All the studies did not report how the allocations were concealed.

Concerning blinding, Ajanova et al. [15] did not state the exact method used. Balbold et al. [5] reported that neither study personnel, nor patients were aware of the intervention. Efremenko et al. [7] reported that only outcomes assessors were blinded. Moreover, Zaitzeva et al. did not report the exact method used for blinding [16] and finally Zaitzeva et al. [8] was an open label.

Selective reporting was difficult to assess, considering the fact that none of the studies reported a protocol being available. Nevertheless, primary endpoints were reported as specified in the study objectives. Ajanova et al. [15] as well as Efremenko et al. [7] provided very limited information relative to the methods.

**Effect of Interventions on smear conversion**

Five trials including 488 participants contributed to this outcome [5,6,7,8,15]. There was evidence of an increased number of patients becoming sputum-negative in the Immunoxel group (RR 3.19; 95% CI −2.44 to 4.17). Heterogeneity was not important among these studies (chi² = 4.04, degree of freedom (DF) = 4 (P < 0.40); I² = 1%) (Fig. 3). The quality of this evidence was low.

**Effect of Interventions on Weight change**

There were two studies that compared ATT alone with ATT + Immunoxel [5, 7, 15] and one study that compared multiple formulations of immunoxel ATT alone with ATT + Immunoxel [6]. Pooled analysis of data provided by 3 studies with 382 participants showed that there was no evidence of a difference in weight change (MD -5.65, 95% CI -0.80 to 12.11). There was a substantial statistical heterogeneity (Tau² = 32.11; Chi² = 212.98, degree of freedom (df = 2) P < 0.00001; I² = 99%) (Fig. 5) and marked clinical heterogeneity between studies contributing to the outcomes. The quality of this evidence was very low.

We also conducted subgroup analysis for this outcome to investigate heterogeneity. This subgroup analysis evaluated ATT alone versus ATT plus placebo, only one study compared Immunoxel to ATT alone (MD 14.30, 95% CI 12.59 to 19.01) [15]. When analysis of this study was separated from the remaining of the studies, the pooled weight change and continue to show a larger increase among participants who received Immunoxel compared to placebo and studies included in the analysis were relatively homogenous (MD 1.40, 95% CI 1.11 to 1.69) (chi² = 25.62, degree of freedom(DF) = 1 (P < 0.00001); I² = 0%). The test for subgroup differences indicated that there is statistically significant subgroup effect (p < 0.00001).

**Effect of Interventions on level of alanine transaminase**

Three studies including 410 participants contributed to this outcome [5, 8, 16]. There was a great reduction in level of alanine transaminase (ALT) among participants receiving Immunoxel compared to ATT alone (SMD −17.90, 95% CI -4.76 to -3.88). There was a substantial statistical heterogeneity among
these studies ($\chi^2 = 169.89$, degree of freedom (DF) = 2 $P < 0.00001$; $I^2 = 99\%$) (Fig. 6) and the quality of evidence was very low. A SMD was used to determine the effect of Immunoxel as included studies used different units to measure alanine transaminase. We also conducted subgroup analysis for this outcome to investigate heterogeneity. This subgroup analysis evaluated ATT alone versus ATT plus placebo, only one study primarily used ATT plus placebo versus Immunoxel ($SMD = 4.32$, 95% CI -4.76 to -3.88) [5]. When analysis of this study was separated from the remaining of the studies, the pooled alanine transaminase continue to show larger change among participants who received Immunoxel compared to placebo and considerable heterogeneity persisted in the analysis ($SMD = 24.87$, 95% CI -40.66 to -9.07) ($\chi^2 = 25.62$, degree of freedom(DF) = 1 ($P < 0.00001$); $I^2 = 96\%$).

**Effect of intervention on total bilirubin**

Two studies evaluated effect of Immunoxel on total bilirubin. The total number of participants in the Immunoxel and control group were 165 and 160, respectively [5,8]. There was no evidence bilirubin reduction among participants receiving Immunoxel compared to control ($SMD = 5.82$, 95% CI -14.99 to 3.35). There was a substantial heterogeneity ($\tau^2 = 43.80$; $\chi^2 = 25545.12$, degree of freedom (df = 1), $P < 0.00001$; $I^2 = 100\%$) (Fig. 7) and marked clinical heterogeneity between studies contributing to the outcomes and the quality of this evidence was very low.

**Effect of intervention on body temperature**

Two trials including 345 participants contributed to this outcome [5,7]. There was evidence of a decreased body temperature among participants in the Immunoxel group (MD = -0.20; 95% CI -0.22 to -0.18), homogeneity was not important ( $\chi^2 = 0.00$, degree of freedom (DF) = 1 ($P = 1.0$); $I^2 = 0\%$) (Fig. 8) the quality of this evidence was low.

**Discussion**

Our systematic review and meta-analysis aimed to assess the effectiveness of adjunctive Immunoxel therapy for the treatment of pulmonary TB. We found six studies with a total of 563 participants, which addressed five outcomes. There was an overall positive effect of Immunoxel in sputum smear conversion, however, studies contributing to this outcome were small and of poor quality findings (low quality of evidence). Moreover the studies made use of, small sample sizes and therefore poor quality of evidence preclude firm conclusions regarding the effect of the Immunoxel as an adjunctive immunotherapy.

Previous investigations also showed that immunoxel resulted in a higher rate of clearance of *M. tuberculosis* in sputum cultures than in patients treated with TB drug alone or with placebo [6,23]. There was no significant difference in body weight gained. However, an improved liver function and decrease in body temperature were noted.

A major limitation of the current review in support of Immunoxel is the small number of the included studies. Small trials can provide firm and definitive answers to questions regarding safety of therapy
when outcomes are dichotomous [24]. However, the findings of small trials are misleading due to random error [25]. Moore et al. demonstrated that for the results to be statistically significant and clinically meaningful, 500 participants per comparison group are needed, which can be achieved by conducting a large trial or by pooling results from multiple studies of small size [26].

A further challenge in this review is the high degree of heterogeneity observed in the outcomes reported across studies. With an exception of the effect of Immunoxel on smear conversion and body temperature, the remaining outcomes varied widely across the different studies.

It is unlikely that we missed any relevant RCTs and non-RCT that could have assessed the clinical benefit of Immunoxel used as adjunct with conventional anti-TB therapy for the treatment of pulmonary TB. Apart from the electronic and manual searches, Immunoxel manufacturers were contacted but unfortunately, we could not obtain any information about studies of Immunoxel from the manufacturer. The current review highlights inappropriate reporting of trials by authors, which makes judgement of the quality of the studies challenging. CONSORT guidelines were established for reporting trials hence journal editors should ensure that these are applied for publishing purposes.

We were unable to formally assess the likelihood of publication bias in this review due to small number of studies included per criterion. However, as publication bias is more likely with small trials, this could be an alternative explanation of the positive findings seen in the studies we identified [27].

**Quality of evidence**

We used the Grade approach to assess the certainty of evidence as shown in the summary of findings table in appendix B. The overall quality of evidence in this review on the use of Immunoxel as adjunctive treatment in patient with pulmonary is low due to high risk of bias. Additionally, we also observed substantial heterogeneity in included studies. Based on the above quality of evidence, the implication is that there is need for further research particularly involving RCT design in order to enhance our quality of evidence.

**Implications for practice and future research**

The current evidence suggests the use of Immunoxel as adjunctive treatment in patients with pulmonary tuberculosis. However, the paucity of data encountered suggests that there is room for more rigorous and carefully designed clinical trials to confirm these findings. Since RCT are the gold standard for testing the effect of new treatment, it would be useful to see adequately powered trials to establish the value of Immunoxel as adjunctive treatment in patients with pulmonary tuberculosis and increase the certainty of the current evidence base.

**Conclusion**

The findings of this systematic review indicate that the use Immunoxel as adjunctive treatment in patients with pulmonary tuberculosis has the potential to enhance the efficacy of the anti-tuberculosis
treatment. However, in order to draw a firm conclusion, methodologically rigorous and well-reported trials are required to confirm these findings. The results of this systematic review also lay an important foundation on which further studies could be built on.

**Abbreviations**

ALT: Alanine transaminase

ATT: anti-tuberculosis treatment

CONSORT: Consolidated Standard of Reporting Trials

DF: Degree of freedom

GRADE: Grading of Recommendations, assessment, Development and Evaluations

HIV: Human Immunodeficiency Virus

IUATLD: International Union Against Tuberculosis and Lung Disease

MD: Mean difference

MDR-TB: Multidrug-resistant Tuberculosis

PRISMA-P: Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols

PROSPERO: Prospective Register of Systematic Reviews

RCT: Randomized Controlled Trials

RR: Relative Risk

SMD: Standardized Mean Difference

TB: Tuberculosis

**Declarations**

**Ethics approval and consent to participate**

Not applicable because no primary data were collected.

**Consent for publication**

Not applicable
Availability of data and materials

All data generated or analysed during this study are included in this published article and its Additional files.

Competing interests

The authors declare that they have no competing interests.

Funding

No funding was received for this systematic review

Authors’ contributions

MK, BP, SP and PN contributed to the conceptualization of the project. MK, BP, SP, MO and PN designed the search strategy, study selection process and drafting of the manuscript. MK, BP, SP, MO and PN contributed to critically reviewing the manuscript. All the authors gave the final approval of the manuscript for publication. PN is the guarantor.

Acknowledgements

Not applicable.

References

1. World Health Organisation (WHO). Global Tuberculosis Report 2020. World Health Organisation. 2020.
2. Zumla A, Chakaya J, Centis R, Ambrosio LD, Mwaba P, Bates M, et al. Tuberculosis treatment and management — an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015; 3(3):220-34.
3. Abate G, Hoft D. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther. 2016; 5: 37-45.
4. Zulkifli Amin SPH. Promising herbals as Adjunctive to standard Antituberculosis Therapy. Indian J Public Health. 2020;11(1):1–8.
5. Batbold U, Butov DO, Kutsyna GA, Damdinpurev N, Grinishina EA, Mijiddorj O, et al. Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an
adjunct immunotherapy in 269 patients with pulmonary tuberculosis. Immunotherapy. 2017;9(1):13–24.

6. Arjanova O V, Prihoda ND, Yurchenko L V. Impact of adjunct immunotherapy with multi-herbal supplement Dzherelo (Immunoxel) on treatment outcomes in end-stage TB/HIV patients. J Antivirals. 2010;1(2):86–8.

7. Efremenko Y V, Arjanova O V, Prihoda ND, Yurchenko L V, Sokolenko NI, Mospan I V, et al. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy. 2012;4(3):273–82.

8. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov YN, Butov DA, Pylypchuk VS, et al. Treatment of cavitory and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo. Clin Microbiol Infect. 2009;15(12):1154–62.

9. Green S, Higgins JPT, Alderson P, Clarke M, Mulrow CD, Oxman AD. Chapter 1: Introduction. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008.

10. RevMan. The Nordic Cochrane Centre, the Cochrane collaboration. Review Manager (RevMan). Version 5.3 Copenhagen. 2014.

11. Cohen J. Statistical power analysis for the behavioural sciences. Hillsdale, N.J.: L. Erlbaum Associates, 1988; 2nd Ed: 567 p.

12. Dijkers M. Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development. 2013;1(5):1–9.

13. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.

14. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.

15. Arjanova O V, Prihoda ND, Yurchenko L V, Sokolenko NI, Vihrova LA, Pylypchuk VS, et al. Enhancement of efficacy of tuberculosis drugs with Immunoxel (Dzherelo™) in HIV-infected patients with active pulmonary tuberculosis. Immunotherapy. 2009;1(4):549–56.

16. Zaitzeva SI., Matveeva SL,Gerasimova TG, Pashkov YN, Butov DA, Pylypchuk VS, Frolov VM, Kutsyna GA. Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standard chemotherapy. Res J Med Sci. 2009;3:36-41

17. Zulkii A, Purnama H.S. Promising herbals as adjunctive to standard antituberculosis therapy. Indian J Public Heal Res Dev. 2017; 8 (2):220-225

18. Butov DA, Efremenko YV, Prihoda ND, Yurchenko LI, Sokolenko NI, Arjanova OV, Stepanenko AL, Butova TS, Zaitzeva SS, Jirathitikal V, Bourinbaiar AS KG. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Futur Med. 2012;687–95.
19. Nikolaeva LG, Maystat T V., Masyuk LA, Pylypchuk VS, Volyanskii YL, Kutsyna GA. Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Des Devel Ther. 2008;(2):87–93.

20. Nikolaeva LG, Maystat T V, Pylypchuk VS, Volyanskii YL, Masyuk LA, Kutsyna GA. Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS. Int Immunopharmacol. 2009;8(6):845–51.

21. Prihoda ND, Arjanova O V, Yurchenko L V, Sokolenko NI, Vihrova LA, Pylypchuk VS, et al. Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT. J Med Plants Res. 2007;1:117–22.

22. Prihoda ND, Olga v. Arjanova, Larisa V. Yurechenko, Nina I. Sokolenko LAV. Adjuvant immunotherapy of Extensively drug resistant tuberculosis (XDR-TB) in Ukraine. Curr Res Tuberc. 2009; 1(1):9-14.

23. Prihoda ND, Arjanova O V, Yurchenko L V, Sokolenko NI, Vihrova LA, Pylypchuk VS, et al. Adjunct Immunotherapy of Tuberculosis in Drug-Resistant TB and TB / HIV Co-Infected Patients. Int J Biomed Pharm Sci. 2008; 2(1):59-64

24. Sackett DL, Cook DJ. Can We Learn Anything from Small Trials? Ann NY Acad Sci. 1993;703(1):25–32.

25. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter? PLoS Med. 2008;5(1):0003–5.

26. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998;78(3):209–16.

27. Faber J, Fonseca LM. How sample size influences research outcomes. Dental Press J Orthod. 2014;19(4):27–9.